Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC) Interventions: Biological: SL-T10; Biological: GX-I7; Biological: Pembrolizumab Sponsors: SL VAXiGEN Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials